Bibliometric analysis of olaparib and pancreatic cancer from 2009 to 2022: A global perspective

Table 1 The top 10 most popular countries/regions conducting research on olaparib and pancreatic cancer

Rank	Country	Counts	TLCS	TGCS
1	United States	83	320	4760
2	China	48	16	366
3	United Kingdom	31	241	3748
4	France	19	140	1537
5	Italy	19	124	1040
6	Germany	16	192	2254
7	Spain	12	186	2352
8	Australia	9	75	1746
9	Belgium	9	130	1391
10	Israel	9	179	2120

TLCS: Total local citation score; TGCS: Total global citation score.

Table 2 The top 20 most popular authors conducting research on olaparib and pancreatic cancer

Rank	Author	Counts	TLCS	TGCS
1	O'Reilly EM	11	135	1177
2	Golan T	9	132	979
3	Hammel P	8	130	956
4	Macarulla T	7	127	947
5	Hochhauser D	5	127	944
6	Seufferlein T	5	17	140
7	Van Cutsem E	5	127	944
8	Algul H	4	131	976
9	Brody JR	4	22	240
10	Cornelissen B	4	4	72
11	Kleger A	4	17	135
12	Lawrence TS	4	18	247
13	Morgan MA	4	18	247
14	Park JO	4	127	942
15	Parsels LA	4	18	247
16	Perkhofer L	4	17	135
17	Arnold D	3	118	919
18	Balmana J	3	68	1407
19	Biankin AV	3	5	49
20	Cavalli A	3	6	36

TLCS: Total local citation score; TGCS: Total global citation score.

Table 3 The 15 most productive institutions regarding olaparib and pancreatic cancer research

Rank	Institution	Country	Counts	TLCS	TGCS
1	Memorial Sloan-Kettering Cancer Center	United States	14	147	1667
2	AstraZeneca	United Kingdom	13	208	2755
3	University of Michigan	United States	10	36	752
4	Harvard Medical School	United States	7	15	173
5	University of Bologna	Italy	7	6	92
6	University of Pennsylvania	United States	7	62	1254
7	Dana-Farber Cancer Institute	United States	6	21	633
8	Beaujon Hospital	France	6	121	931
9	Tel Aviv University	Israel	6	110	907
10	University of Oxford	United Kingdom	6	18	192
11	University of Texas, MD Anderson Cancer Center	United States	6	27	859
12	Vall d’Hebron University Hospital	Spain	6	130	1163
13	Sheba Medical Center	Israel	5	70	1220
14	University College London	United Kingdom	5	127	1150
15	University of Glasgow	United Kingdom	5	7	105

TLCS: Total local citation score; TGCS: Total global citation score.

Table 4 The top 10 journals publishing research on olaparib and pancreatic cancer

Rank	Journal	Counts	IF 2021	TLCS	TGCS
1	Cancers	13	6.575	0	94
2	Clinical Cancer Research	7	13.801	16	169
3	International Journal of Molecular Sciences	5	6.208	0	14
4	Annals of Oncology	4	51.769	43	566
5	European Journal of Medicinal Chemistry	4	7.088	8	139
6	Journal of Clinical Oncology	4	50.717	74	1293
7	BMC Cancer	3	4.638	0	13
8	British Journal of Cancer	3	9.075	6	99
9	Cancer Biology & Therapy	3	4.875	0	6
10	Cancer Research	3	13.312	11	75

TLCS: Total local citation score; TGCS: Total global citation score.

Table 5 The top 10 cocited references related to olaparib and pancreatic cancer

Rank	Ref.	Title	Citations	Journal
1	Golan et al[11], 2019	Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic cancer	103	The New England Journal of Medicine
2	Kaufman et al[35], 2015	Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation	56	Journal of Clinical Oncology
3	Farmer et al[36], 2005	Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy	52	Nature
4	Robson et al[10], 2017	Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation	46	The New England Journal of Medicine
5	Bryant et al[37], 2005	Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase	44	Nature
6	Murai et al[38], 2012	Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors	40	Cancer Research
7	Waddell et al[39], 2015	Whole genomes redefine the mutational landscape of pancreatic cancer	39	Nature
8	Fong et al[40], 2009	Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers	37	The New England Journal of Medicine
9	Moore et al[21], 2018	Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer	37	The New England Journal of Medicine
10	Conroy et al[4], 2011	FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer	36	The New England Journal of Medicine